e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Airway disease-associated exacerbations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Identifying tools to investigate outcomes following an exacerbation of COPD
P. Burrage (Brisbane, Australia), A. Halner (Oxford, United Kingdom), D. Nicolau (Brisbane, Australia), M. Bafadhel (Oxford, United Kingdom)
Source:
International Congress 2019 – Airway disease-associated exacerbations
Session:
Airway disease-associated exacerbations
Session type:
Thematic Poster
Number:
4300
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Burrage (Brisbane, Australia), A. Halner (Oxford, United Kingdom), D. Nicolau (Brisbane, Australia), M. Bafadhel (Oxford, United Kingdom). Identifying tools to investigate outcomes following an exacerbation of COPD. 4300
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Do cardiac biomarkers predict long-term outcomes from exacerbations of COPD?
Source: International Congress 2017 – Highlights on clinical problems in COPD
Year: 2017
Comparison of multidimensional assessment systems with regard to risk prediction for exacerbations of COPD
Source: Annual Congress 2011 - COPD exacerbation
Year: 2011
Acute exacerbation phenotypes of asthma and COPD: impact on clinical outcomes
Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations
Year: 2021
Efficiency of different approaches for the assessment of the risk of exacerbations in patients with COPD
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
Predicting treatment outcomes following an exacerbation of airways disease
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
Identifying asthma features in severe COPD
Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS)
Year: 2018
Clinical clustering of COPD patients is useful to predict future COPD exacerbations
Source: International Congress 2018 – New predictors of morbidity and mortality in COPD
Year: 2018
The effectiveness of early pulmonary rehabilitation in acute exacerbation of COPD in the terms of functional and systemic markers.
Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation
Year: 2020
Using characteristics of asthma phenotypes to determine exacerbation severity
Source: Virtual Congress 2020 – Phenotypes of obstructive diseases
Year: 2020
Clinical and exacerbation characteristics may predict treatment response in acute exacerbations of COPD
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018
Early occurrence of any COPD exacerbation predicts further higher risk of moderate/severe exacerbations regardless of recording tool: the FLAME study
Source: International Congress 2017 – Management of COPD
Year: 2017
Modelling and simulation in successful drug development programmes: Characterisation of exacerbation reduction with roflumilast to corroborate the importance of defining patient subsets in COPD
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Defining acute asthma severity – how do worldwide asthma guidelines compare?
Source: International Congress 2018 – The bad and the ugly in paediatric asthma: comorbidities and exacerbations
Year: 2018
Combining digital technologies to monitor asthma control and predict asthma exacerbations
Source: Virtual Congress 2020 – Digital health: a brave new world?
Year: 2020
Measuring and quantifying acute exacerbations of COPD: pitfalls and practicalities
Source: Eur Respir J 2014; 43: 662-664
Year: 2014
Can we predict who is mostly likely to re-exacerbate after a COPD exacerbation?
Source: Annual Congress 2008 - Prognosis in COPD
Year: 2008
Efficiency of different multidimensional indexes for the assessment of the risk of exacerbations in patients with COPD
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Important attributes of COPD exacerbations: a conjoint analysis
Source: Eur Respir J 2004; 24: Suppl. 48, 514s
Year: 2004
Cardiac biomarkers and outcomes of COPD exacerbations
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept